It has previously been described that ACLY is overexpressed in malignant tissues as compared to normal tissues, which could provide for an optimal therapeutic window, yet the cause of overexpression of ACLY in HNSCC patients has not been investigated [23]. This evidence concerns the gene ACLY and head and neck squamous cell carcinoma.